Featured Research

from universities, journals, and other organizations

Experimental drug beneficial in trial to treat a rare sarcoma

Date:
May 7, 2013
Source:
National Cancer Institute (NCI) at NIH
Summary:
Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib.

CT scan from 25 year-old patient with newly diagnosed metastatic ASPS; top scan is cross-section of the chest at the start of the trial and bottom scan is post-treatment, with significant tumor shrinkage.
Credit: NCI

Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib. The results from this largest clinical trial on ASPS to date were published online ahead of print on April 29, 2013, in the Journal of Clinical Oncology.

The phase II trial was funded by the National Cancer Institute (NCI), part of the National Institutes of Health.

ASPS accounts for less than 1 percent of soft tissue sarcomas, cancers that originate in connective and supportive tissue, and occurs mostly in people ages 15 to 35. The tumor relies on the growth of new blood vessels to obtain oxygen and nutrients and to facilitate its spread to the lungs, brain, and bones. Surgical removal of these tumors is the recommended treatment. However, not all patients are candidates for surgical resection based on extent of disease or other conditions. Standard anticancer therapy has not been effective for treating patients with metastatic ASPS. The median survival time for patients with unresectable metastatic ASPS is 40 months, with a 5-year survival rate of 20 percent.

Cediranib is a drug that inhibits a class of proteins called vascular endothelial growth factor receptors which regulate blood vessel formation. The drug, developed by AstraZeneca, Wilmington, Del., has been tested in clinical trials against other cancers, including non-small cell lung cancer, kidney cancer, and colorectal cancer, with varying degrees of benefit.

The 43 patients with metastatic ASPS on the trial were given a 30 milligram oral dose of cediranib once daily until either their disease progressed or they developed significant side effects. To date, the objective response rate, which requires a more than 30 percent reduction in tumor size of target lesions, is 35 percent (15 of the 43 patients achieved a partial response). An additional 26 patients, or 60 percent, have stable disease.

"It's unusual to see such high rates of tumor shrinkage in a cancer that traditionally has not responded to standard chemotherapy treatments used for sarcomas," said Shivaani Kummar, M.D., NCI principal investigator for this trial. "Our ability to bring patients with ASPS from across the country to the clinical facility on the NIH campus for treatment has made it possible to rapidly test this new drug in this rare tumor."

To understand how cediranib works in ASPS and to identify abnormalities that may help in the selection of future therapies, tumor biopsy specimens were obtained before treatment and again during the first week of treatment. When the investigators compared gene expression in these two specimen groups, they discovered that the samples taken after treatment had lower expression of two genes that are important in regulating blood vessel development: ANGPT2 and FLT1.

Based on the encouraging responses observed in this trial, the researchers have initiated a follow-up trial that is comparing the effectiveness of cediranib to another vascular endothelial growth factor receptor drug, called sunitinib, in patients with metastatic ASPS.

The clinical trials identifier for this study is: NCT00942877.


Story Source:

The above story is based on materials provided by National Cancer Institute (NCI) at NIH. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Kummar, D. Allen, A. Monks, E. C. Polley, C. D. Hose, S. P. Ivy, I. B. Turkbey, S. Lawrence, R. J. Kinders, P. Choyke, R. Simon, S. M. Steinberg, J. H. Doroshow, L. Helman. Cediranib for Metastatic Alveolar Soft Part Sarcoma. Journal of Clinical Oncology, 2013; DOI: 10.1200/JCO.2012.47.4288

Cite This Page:

National Cancer Institute (NCI) at NIH. "Experimental drug beneficial in trial to treat a rare sarcoma." ScienceDaily. ScienceDaily, 7 May 2013. <www.sciencedaily.com/releases/2013/05/130507103031.htm>.
National Cancer Institute (NCI) at NIH. (2013, May 7). Experimental drug beneficial in trial to treat a rare sarcoma. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2013/05/130507103031.htm
National Cancer Institute (NCI) at NIH. "Experimental drug beneficial in trial to treat a rare sarcoma." ScienceDaily. www.sciencedaily.com/releases/2013/05/130507103031.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins